A deletion involving chromosome 3p (14-23) characteristically occurs in small cell lung cancer (SCLC). Reduction to homozygosity, rather than complete loss, is typically observed for genes in the deleted region. Lack of expression for genes encoded by this region, implying inactivation of all alleles, has not been previously described. We have examined the expression of aminoacylase-1 (ACY-1), encoded by chromosome 3p21, using both an electrophoretic activity assay and a monoclonal antibody-based ELISA. A variety of human tissues, including lung, brain, liver, kidney, heart, adrenal medulla, and erythrocytes have previously been tested for ACY-1 activity and antigen; all but erythrocytes are positive. Thus, ACY- 
Introduction
Based on clinical and epidemiologic observations, Knudsen, and subsequently Comings, hypothesized that in the develop-ment of specific neoplasms certain genes are inactivated (1, 2) . In inherited forms of specific neoplasms this inactivation is due to a defective germ line allele with a somatic mutation affecting the remaining normal gene. In sporadic forms of these tumors two somatic mutations are hypothesized to have occurred. Cytogenetic observations of tumor-specific deletions, typically visibly affecting only one copy of a chromosome, have provided suggestive evidence for the location of such genes, termed tumor suppressor genes (3) . In retinoblastoma, associated with a deletion of chromosome 13q14, further delineation ofthe tumor suppressor locus was provided by the discovery that the gene encoding the enzyme esterase D is tightly linked to the Rb gene (4) . The Rb gene has now been isolated and found to display abnormalities of expression at the mRNA and protein levels in retinoblastoma cell lines and tumors (5) (6) (7) (8) . Recently, frequent inactivation of the Rb gene has been described in both small cell lung cancer (SCLC)' and breast cancer (9-1 1) .
SCLC displays a characteristic loss of genetic material, usually in the form of a deletion, involving the short arm of chromosome 3, detected both cytogenetically and by the molecular demonstration of loss of alleles (12) (13) (14) (15) . The dimensions of the deletion are variable, but the region 3p2 1 appears to be universally involved, as DNA probes for the 3p2 1 locus DNF 15S2 are reduced to homozygosity in all cases of unequivocal SCLC reported to date (13) (14) (15) . However, complete inactivation of a chromosome 3p21 gene in SCLC has not previously been reported.
Aminoacylase-1 (ACY-1; N-acylaminoacid aminohydrolase, EC 3.4.1.14) is a cytosolic enzyme widely distributed in mammalian tissues that catalyzes the hydrolysis of acylated amino acids into amino acids and acyl groups. The role of the enzyme in cellular physiology is unknown, but it has been postulated to function in the catabolism of amino-terminally acylated proteins (16) . Because ACY-1 has been assigned to chromosome 3p21 (17, 18) , we examined its expression in SCLC. ACY-1 is frequently not detectable in SCLC, but has been detectable in all other neoplasms and normal tissues (with the exception of erythrocytes) examined to date. Thus, ACY-1 inactivation is highly specific for SCLC. These findings support the dual inactivation of chromosome 3p21 genes in SCLC, suggest that the ACY-1 and SCLC tumor suppressor genes are closely linked, and may aid in the isolation of an SCLC tumor suppressor gene.
1. Abbreviations used in this paper: ACY-1, aminoacylase-l; LDH, lactate dehydrogenase; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
Methods
Cell lines, culture, and preparation ofsamples. SCLC, non-small cell lung cancer (NSCLC), and other human cell lines were established and propagated as described (19) .
Cell lines were harvested, washed twice in PBS (pH 7.4), resuspended in a volume of distilled water approximately equal to that of the cell pellet, and freeze-thawed three times. After centrifugation for 5 min in a high speed microfuge (model 5412; Eppendorf, Hamburg, West Germany) supernatants were removed and protein was determined and then frozen at -70°C (20 ACY-1 ELISA. A previously described sandwich-type immunoassay using the anti-ACY-l MAb 3D12 as capture antibody and rabbit anti-ACY-l serum to detect immunoimmobilized ACY-1 was used for the measurement of ACY-1 antigen (21). Standard curves were constructed using varying dilutions of a partially purified ACY- 
Results
Enzyme activity ofcell lines and tumor samples. 29 SCLC cell lines were assayed for ACY-1 activity: 11 were positive, 13 reduced, and 5 undetectable (Table I) Because tumors can undergo additional phenotypic alterations after being established in culture as cell lines, we examined ACY-l activity in tissue from eight SCLC tumors obtained either at autopsy or surgery, and in tissue from nine NSCLC and eight colon carcinomas obtained at surgery. Four SCLC tumors were positive, three reduced, and one undetectable; in none ofthe other tumors was ACY-1 reduced or undetectable (P < 0.01, Fisher's exact test). The SCLC tumor that was ACY-1 negative was a subcutaneous metastasis that was surgically removed, immediately frozen at -70'C, then assayed for ACY-l activity within 1 wk, making ACY-1 degradation very unlikely in that particular sample (Fig. 2) .
ACY-l activity was stable in samples frozen for at least 6 mo and was not notably affected by freeze-thawing up to five times after initial preparation. However, to control for possible degradation of enzyme activity, all samples in which ACY-1 was undetectable or reduced were assayed for LDH isozymes encoded by nonlinked chromosomal loci by a similar semiquantitative electrophoretic assay. No diminution in LDH activity was observed (Figs. 2 and 3) . To determine whether a soluble inhibitor might be responsible for the decreased ACY-I activities seen in SCLC samples, equal amounts of ACY-1 negative and positive samples were mixed and assayed. No reduction in activity was apparent.
ACY-J ELISA. ACY-1 antigen was quantitated by ELISA in all 29 SCLC and in 24 other human cell lines (Table I ). The quantitative ELISA results correlate well with the semiquantitative activity assay (Spearman's rank correlation, r, = 0.794; P < 0.001) as would be expected if both are measuring the same enzyme. Three SCLC samples were negative by ELISA but had a small level of ACY-I activity; one sample had no detectable activity but displayed small levels of ACY-1 antigen. Four SCLC cell lines (National Cancer Institute (NCI) H187, NCI H711, NCI H1008, and NCI H1092) lacked ACY-I by both antigen and activity assays. ACY-I content of SCLC cell lines was significantly less than that of NSCLC (P < 0.001) and other (P < 0.01) cell lines (Wilcoxon rank sum test).
Antigen was also quantitated in all tumor tissue samples (Fig. 4) . The SCLC tumor sample that lacked detectable ACY-1 antigen also lacked detectable ACY-l activity. ACY-l content of SCLC tumor Famples was significantly less than that of NSCLC (P < 0.02) and colon (P < -0.001) tumors (Wilcoxon rank sum test).
Discussion
The deletion of chromosome 3p (14-23) characteristic for SCLC has been confirmed on a cytogenetic and molecular basis by several groups (12) (13) (14) (15) . Cytogenetic analysis typically reveals at least one normal copy of chromosome 3 in SCLC isolates (12) . Furthermore, molecular analyses have revealed that at least one copy of all genes examined to date encoded by Aminoacylase-l Expression in Small Cell Lung Cancer 2121 figure. in human erythrocytes (21) . Other investigators have reported similar expression in rodent tissues (26, 27 
